Mr Stephen Gamble
Currently working in molecular biology in the Cancer, Ageing and Somatic Mutation (CASM) team at the Sanger Institute. My work programme is determined by requests from more senior scientists.
My current work only partially involves neurological material and cell lines, both from tumours and other neurological disease. Apart from primary tumours the nervous system is a common site for secondary tumours for some forms of cancer. In addition, some types of tumour cell are dervived embryologically from neural crest, for example melanocytes and some forms of intestinal tumour.
Previously I have worked on the biological basis of mental illness using neurobiology, biochemistry and computing. I am also interested in the analysis of sequential behaviour.
Outside this I follow my own areas of interest. I am interested in the roles of mitochondria and autoimmunity in neurological disease, and the involvement of gene mutations found in cancers also in these diseases.
No collaborators listed
Associated News Items
Annett LE, Ridley RM, Gamble SJ, Baker HF (1989), “Social withdrawal following amphetamine administration to marmosets.” Psychopharmacology (Berl) 99(2):222-9 Details
Taylor GR, Crow TJ, Carter GI, Gamble SJ (1985), “Cytopathogenic cerebrospinal fluid from neurological and psychiatric patients.” Exp Mol Pathol 42(2):271-7 Details
Taylor GR, Roberts GW, Crow TJ, Royds JA, Gamble SJ, Taylor CB, Carter GI, Timperley WR (1985), “The cytopathogenic agent in CSF: evidence for a relationship with enolase levels.” J Neurol Neurosurg Psychiatry 48(3):281 Details
Annett LE, Ridley RM, Gamble SJ, Baker HF (1983), “Behavioural effects of intracerebral amphetamine in the marmoset.” Psychopharmacology (Berl) 81(1):18-23 Details
Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ (1983), “Adverse effects of anticholinergic medication on positive schizophrenic symptoms.” Psychol Med 13(3):513-27 Details
Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.” Science 220(4596):530-2 Details
Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983), “Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.” Adv Biochem Psychopharmacol 37:299-308 Details
Waddington JL, Gamble SJ (1981), “Prolonged dopamine receptor blockade in rats after termination of long-term depot fluphenazine.” Lancet 1(8234):1375-6 Details
Waddington JL, Gamble SJ, Bourne RC (1981), “Sequelae of 6 months continuous administration of cis(Z)-and trans(E)-flupenthixol in the rat.” Eur J Pharmacol 69(4):511-3 Details
Owen F, Cross AJ, Waddington JL, Poulter M, Gamble SJ, Crow TJ (1980), “Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration.” Life Sci 26(1):55-9 Details
Waddington JL, Gamble SJ (1980), “Emergence of apomorphine-induced 'vacuous chewing' during 6 months continuous treatment with fluphenazine decanoate.” Eur J Pharmacol 68(3):387-8 Details
Waddington JL, Gamble SJ (1980), “Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.” Eur J Pharmacol 67(4):363-9 Details
Waddington JL, Gamble SJ (1980), “Differential effects of ageing on distinct features of apomorphine stereotypy in the adult rat.” Neurosci Lett 20(1):95-9 Details
Waddington JL, Gamble SJ (1980), “Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.” Psychopharmacology (Berl) 71(1):75-7 Details